On Friday, VBL Therapeutics Ltd. (formerly Vascular Biogenics) published a draft prospectus with the US Securities and Exchange Commission (SEC) to raise up to $75 million, including the underwriters’ over-allotment option, on Nasdaq. The drug development company did not disclose the company value for the offering. The underwriters are Deutsche Bank Securities LLC, Wells Fargo, JPMorgan, and Oppenheimer.
Help employers find you! Check out all the jobs and post your resume.
